The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews

References

• Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9
   PubMed Web of Science ®Google Scholar
• Kortt MA, Bootman JL. The economics of benign prostatic hyperplasia treatment: a literature review. Clin Ther 1996;18:1227-41
   PubMed Web of Science ®Google Scholar
• Barry MJ, Fowler FJ, Bin L. A nationwide survey of practicing urologists: current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997;158:488-91
   PubMed Web of Science ®Google Scholar
• Clifford GM, Farmer RDT. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol 2000;38:2-19
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology 2001;58:642-50
   PubMed Web of Science ®Google Scholar
• Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004;94:738-44
   PubMed Web of Science ®Google Scholar
• AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter1: Diagnosis and treatment recommendations. J Urol 2003;170:530-47
   PubMed Web of Science ®Google Scholar
• Goldenberg SL, Ramsey E, Trachtenberg J. Alpha-blocker therapy for benign prostatic hyperplasia: a comparative review. Can J Urol 1998;5:551-7
   PubMedGoogle Scholar
• Jonler M, Riehmann M, Bruskewitz RC. Benign prostatic hyperplasia: current pharmacological treatment. Drugs 1994;47:66-81
   PubMed Web of Science ®Google Scholar
• Wilde MI, Fitton A, Sorkin EM. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993;3:258-77
   PubMed Web of Science ®Google Scholar
• Mendelsohn R, Thompson D. Drug treatment for benign prostatic hyperplasia. Health authorities must audit use of finasteride. BMJ 1997;315:370-1
   PubMed Web of Science ®Google Scholar
• Becker LA, Oxman AD. Chapter 22: Overviews of reviews, Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from: www.cochrane-handbook.org
   Google Scholar
• Search Strategy Used to Create the Systematic Reviews Subset on PubMed, [Online]Available: http://my.opera.com/thanksend/blog/show.dml/15843432 (May 5th, 2011)
   Google Scholar
• Beverley JS, Jeremy MG, George AW. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007;15:7-10
   Google Scholar
• Canadian Coordinating Office for Health Technology Assessment: Proposed Evaluation Tools for COMPUS, [Online] Available: https://www.ccohta.ca/compus/compus_pdfCOMPUS_Evaluation_Methodology_draft_e.pdf
   Google Scholar
• Guyatt GH, Oxman AD, Kunz R, et al. GRADE Working Group. What is ‘quality of evidence’ and why is it important to clinicians? BMJ 2008;336:995-8
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Welton NJ, et al. NICE DSU Technical Support Document 3: Heterogeneity: subgroups, meta-regression, bias and bias-adjustment (last updated April 2012). 2011. Available from http://www.nicedsu.org.uk
   Google Scholar
• Jonathan JD, Julian PT, Douglas GA. Chapter 9: Analysing data and undertaking meta-analyses, Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org
   Google Scholar
• Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;3:b1147
   Web of Science ®Google Scholar
• Dias S, Welton N, Sutton AJ, et al. NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials (last updated April 2012). 2011. Available from http://www.nicedsu.org.uk
   Google Scholar
• MacDonald R, WiltR TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005;66:780-8
   PubMed Web of Science ®Google Scholar
• Wilt TJ, MacDonald R. Doxazosin in the treatment of benign prostatic hypertrophy: an update. Clin Interv Aging 2006;1:389-401
   PubMed Web of Science ®Google Scholar
• Liu D, Lu Y, Shao J. Comparison of controlled release doxazosin and tamsulosin in treating benign prostatic hyperplasia: a systematic review. J Med Res 2009;38:63-6
   Google Scholar
• Garimella PS, Fink HA, Macdonald R, et al. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev 2009;4:CD007360
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Howe RW, Rutks IR, et al. Terazosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002;4:CD003851
   PubMedGoogle Scholar
• Xiong Yi, Ye L, Ren Y, et al. Evaluation of the effectiveness of terazosin, tamsulosin and finasteride for benign prostatic hyperplasia. Chinese Evidence-Based Med 2005;5:448-54
   Google Scholar
• Ye L, Ren Y, Li Y, et al. Evaluation of the safety of terazosin, tamsulosin and finasteride for benign prostatic hyperplasia. Adverse Drug Reactions J 2005;6:412-17
   Google Scholar
• Boyle P, Robertson C, Manski R, et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58:717-22
   PubMed Web of Science ®Google Scholar
• Mudiyala R, Ahmed A. Effect of terazosin on clinical benign prostatic hyperplasia in older adults. J Am Geriatr Soc 2003;51:424-6
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003;1:CD002081
   PubMedGoogle Scholar
• Dong Z, Wang Z, Yang K, et al. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med 2009; 55:129-36
   PubMed Web of Science ®Google Scholar
• Gu D. A systematic review of tamsulosin compared with terazosin for patient with benign prostatic hyperplasia. Int J Urol Nephrol 2009;29:177-81
   Google Scholar
• Ren Y, Li N, Ye L, et al. Comparison of tamsulosin and terazosin in treating benign prostatic hyperplasia: a systematic review. J Clin Urol 2006; 21:692-7
   Google Scholar
• Ren R, Lan XX. Efficacy and safety of tamsulosin for the treatment of benign prostatic hyperplasia:a Meta-analysis. J Shanxi Med Univ 2008;39:1036-40
   Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59
   PubMed Web of Science ®Google Scholar
• Tiong HY, Tibung MJ, Macalalag M, et al. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urol Int 2009;83:44-8
   PubMed Web of Science ®Google Scholar
• Roehrborn CG. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006;97:734-41
   PubMed Web of Science ®Google Scholar
• Resnick MI, Roehrborn CG. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Prostate Cancer and Prostatic Diseases 2007;10:155-9
   PubMed Web of Science ®Google Scholar
• Li NC, Wu SL, Jin J, et al. Comparison of different drugs on the treatment of benign prostate hyperplasia. Zhonghua Wai Ke Za Zhi 2007;45:947-50
   PubMedGoogle Scholar
• Roehrborn CG, Prajsner A, Kirby R, et al. A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia. Eur Urol 2005;48:445-52
   PubMed Web of Science ®Google Scholar
• Agrawal MS, Yadav A, Yadav H, et al. A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol 2009;25:474-8
   PubMedGoogle Scholar
• Samli MM, Dincel C. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. Urol Int 2004;73:125-9
   PubMed Web of Science ®Google Scholar
• Hanyu S, Hatano A, Nishiyama T, et al. A randomized controlled study comparing clinical effects of naftopidil and tamsulosin on benign prostatic hyperplasia. Hinyokika Kiyo 2010;56:489-94
   PubMedGoogle Scholar
• Masumori N, Tsukamoto T, Iwasawa A, et al. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urol Int 2009;83:49-54
   PubMed Web of Science ®Google Scholar
• John PA, Ioannidis MD. Integration of evidence from multiple Meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments Meta-analyses. CMAJ 2009;181:488-93
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900
   PubMed Web of Science ®Google Scholar